Moderna, Inc. (NASDAQ:MRNA) Receives Average Rating of “Hold” from Analysts

Moderna, Inc. (NASDAQ:MRNA) has received an average recommendation of “Hold” from the twenty-one analysts that are currently covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a sell recommendation, twelve have assigned a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $36.4286.

Several research firms recently issued reports on MRNA. Weiss Ratings restated a “sell (e+)” rating on shares of Moderna in a research report on Wednesday, October 8th. Barclays cut their price target on shares of Moderna from $31.00 to $25.00 and set an “equal weight” rating for the company in a report on Friday. JPMorgan Chase & Co. reduced their price target on shares of Moderna from $26.00 to $25.00 and set an “underweight” rating on the stock in a research report on Thursday, October 23rd. Citigroup lowered their price objective on Moderna from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Thursday, October 23rd. Finally, Evercore ISI set a $32.00 target price on Moderna in a research note on Friday, August 1st.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Norges Bank acquired a new position in Moderna during the second quarter worth $94,910,000. Federated Hermes Inc. grew its stake in shares of Moderna by 364.5% in the second quarter. Federated Hermes Inc. now owns 2,869,271 shares of the company’s stock valued at $79,163,000 after buying an additional 2,251,497 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Moderna by 19.1% in the second quarter. Geode Capital Management LLC now owns 8,877,280 shares of the company’s stock valued at $244,458,000 after buying an additional 1,420,690 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Moderna by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 41,708,705 shares of the company’s stock valued at $1,150,743,000 after buying an additional 1,312,192 shares during the period. Finally, Invesco Ltd. lifted its stake in Moderna by 20.7% during the 2nd quarter. Invesco Ltd. now owns 7,101,032 shares of the company’s stock worth $195,917,000 after acquiring an additional 1,217,408 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Performance

Shares of Moderna stock opened at $24.54 on Monday. The business’s 50 day moving average price is $25.81 and its 200 day moving average price is $27.14. The company has a market cap of $9.59 billion, a price-to-earnings ratio of -3.04 and a beta of 2.02. Moderna has a one year low of $23.04 and a one year high of $50.90.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.15) by $1.64. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $893.29 million. During the same period last year, the company earned $0.03 EPS. The company’s revenue for the quarter was down 45.4% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. On average, analysts predict that Moderna will post -9.61 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.